nodes	percent_of_prediction	percent_of_DWPC	metapath
Lamivudine—ABCC1—Dactinomycin—testicular cancer	0.0539	0.0708	CbGbCtD
Lamivudine—ABCC3—Cisplatin—testicular cancer	0.0504	0.0663	CbGbCtD
Lamivudine—ABCC3—Etoposide—testicular cancer	0.0495	0.0651	CbGbCtD
Lamivudine—ABCC1—Epirubicin—testicular cancer	0.039	0.0513	CbGbCtD
Lamivudine—ABCG2—Dactinomycin—testicular cancer	0.0361	0.0474	CbGbCtD
Lamivudine—ABCC3—Doxorubicin—testicular cancer	0.0338	0.0444	CbGbCtD
Lamivudine—ABCC1—Vinblastine—testicular cancer	0.0338	0.0444	CbGbCtD
Lamivudine—ABCC3—Methotrexate—testicular cancer	0.0327	0.043	CbGbCtD
Lamivudine—SLC22A2—Vinblastine—testicular cancer	0.0306	0.0402	CbGbCtD
Lamivudine—ABCC1—Etoposide—testicular cancer	0.0304	0.04	CbGbCtD
Lamivudine—SLC22A2—Cisplatin—testicular cancer	0.0281	0.0369	CbGbCtD
Lamivudine—ABCC2—Carboplatin—testicular cancer	0.0268	0.0352	CbGbCtD
Lamivudine—ABCC4—Methotrexate—testicular cancer	0.025	0.0329	CbGbCtD
Lamivudine—ABCC2—Vinblastine—testicular cancer	0.025	0.0328	CbGbCtD
Lamivudine—ABCG2—Carboplatin—testicular cancer	0.0242	0.0319	CbGbCtD
Lamivudine—ABCC2—Cisplatin—testicular cancer	0.0229	0.0301	CbGbCtD
Lamivudine—ABCC2—Etoposide—testicular cancer	0.0225	0.0296	CbGbCtD
Lamivudine—ABCC1—Doxorubicin—testicular cancer	0.0207	0.0273	CbGbCtD
Lamivudine—ABCG2—Cisplatin—testicular cancer	0.0207	0.0272	CbGbCtD
Lamivudine—ABCG2—Etoposide—testicular cancer	0.0204	0.0267	CbGbCtD
Lamivudine—ABCC1—Methotrexate—testicular cancer	0.0201	0.0264	CbGbCtD
Lamivudine—ABCC2—Doxorubicin—testicular cancer	0.0154	0.0202	CbGbCtD
Lamivudine—ABCC2—Methotrexate—testicular cancer	0.0149	0.0195	CbGbCtD
Lamivudine—ABCG2—Doxorubicin—testicular cancer	0.0139	0.0182	CbGbCtD
Lamivudine—ABCG2—Methotrexate—testicular cancer	0.0134	0.0177	CbGbCtD
Lamivudine—ABCB1—Dactinomycin—testicular cancer	0.013	0.0171	CbGbCtD
Lamivudine—SLC22A6—Methotrexate—testicular cancer	0.0109	0.0143	CbGbCtD
Lamivudine—ABCB1—Vinblastine—testicular cancer	0.00815	0.0107	CbGbCtD
Lamivudine—ABCB1—Cisplatin—testicular cancer	0.00747	0.00982	CbGbCtD
Lamivudine—ABCB1—Etoposide—testicular cancer	0.00734	0.00965	CbGbCtD
Lamivudine—PCYT2—gonad—testicular cancer	0.00531	0.0681	CbGeAlD
Lamivudine—ABCB1—Doxorubicin—testicular cancer	0.00501	0.00658	CbGbCtD
Lamivudine—ABCB1—Methotrexate—testicular cancer	0.00485	0.00637	CbGbCtD
Lamivudine—PGK1—gonad—testicular cancer	0.00456	0.0585	CbGeAlD
Lamivudine—PCYT2—testis—testicular cancer	0.00383	0.0491	CbGeAlD
Lamivudine—PCYT1A—gonad—testicular cancer	0.00362	0.0464	CbGeAlD
Lamivudine—NME2—embryo—testicular cancer	0.00335	0.043	CbGeAlD
Lamivudine—PGK1—testis—testicular cancer	0.00329	0.0422	CbGeAlD
Lamivudine—NT5C—female gonad—testicular cancer	0.00313	0.0402	CbGeAlD
Lamivudine—NT5C—testis—testicular cancer	0.00278	0.0356	CbGeAlD
Lamivudine—PCYT1A—testis—testicular cancer	0.00261	0.0334	CbGeAlD
Lamivudine—CMPK1—gonad—testicular cancer	0.00233	0.0299	CbGeAlD
Lamivudine—NME1-NME2—lymph node—testicular cancer	0.00217	0.0279	CbGeAlD
Lamivudine—NT5C—lymph node—testicular cancer	0.00201	0.0258	CbGeAlD
Lamivudine—NME1—female gonad—testicular cancer	0.00196	0.0252	CbGeAlD
Lamivudine—CMPK1—female gonad—testicular cancer	0.00189	0.0243	CbGeAlD
Lamivudine—NME2—female gonad—testicular cancer	0.00185	0.0237	CbGeAlD
Lamivudine—NME1—testis—testicular cancer	0.00174	0.0224	CbGeAlD
Lamivudine—DCK—embryo—testicular cancer	0.00171	0.0219	CbGeAlD
Lamivudine—CMPK1—testis—testicular cancer	0.00168	0.0215	CbGeAlD
Lamivudine—NME2—testis—testicular cancer	0.00164	0.0211	CbGeAlD
Lamivudine—DCK—seminal vesicle—testicular cancer	0.00161	0.0206	CbGeAlD
Lamivudine—SLC22A3—embryo—testicular cancer	0.00139	0.0179	CbGeAlD
Lamivudine—SLC22A3—seminal vesicle—testicular cancer	0.00131	0.0168	CbGeAlD
Lamivudine—NME1—lymph node—testicular cancer	0.00126	0.0162	CbGeAlD
Lamivudine—CMPK1—lymph node—testicular cancer	0.00122	0.0156	CbGeAlD
Lamivudine—NME2—lymph node—testicular cancer	0.00119	0.0153	CbGeAlD
Lamivudine—DCK—gonad—testicular cancer	0.00116	0.0149	CbGeAlD
Lamivudine—ABCC1—seminal vesicle—testicular cancer	0.00108	0.0139	CbGeAlD
Lamivudine—DCK—Doxorubicin—Epirubicin—testicular cancer	0.000985	0.519	CbGdCrCtD
Lamivudine—SLC22A3—gonad—testicular cancer	0.000946	0.0121	CbGeAlD
Lamivudine—DCK—female gonad—testicular cancer	0.000943	0.0121	CbGeAlD
Lamivudine—DCK—Epirubicin—Doxorubicin—testicular cancer	0.000911	0.481	CbGdCrCtD
Lamivudine—ABCC3—female gonad—testicular cancer	0.000903	0.0116	CbGeAlD
Lamivudine—ABCG2—seminal vesicle—testicular cancer	0.000896	0.0115	CbGeAlD
Lamivudine—DCK—testis—testicular cancer	0.000836	0.0107	CbGeAlD
Lamivudine—ABCC3—testis—testicular cancer	0.0008	0.0103	CbGeAlD
Lamivudine—SLC22A3—female gonad—testicular cancer	0.000768	0.00986	CbGeAlD
Lamivudine—ABCC4—female gonad—testicular cancer	0.000745	0.00956	CbGeAlD
Lamivudine—SLC22A3—testis—testicular cancer	0.000681	0.00874	CbGeAlD
Lamivudine—ABCC4—testis—testicular cancer	0.000661	0.00848	CbGeAlD
Lamivudine—ABCC2—testis—testicular cancer	0.00064	0.0082	CbGeAlD
Lamivudine—ABCC1—female gonad—testicular cancer	0.000635	0.00815	CbGeAlD
Lamivudine—DCK—lymph node—testicular cancer	0.000606	0.00777	CbGeAlD
Lamivudine—ABCC3—lymph node—testicular cancer	0.00058	0.00744	CbGeAlD
Lamivudine—ABCC1—testis—testicular cancer	0.000563	0.00723	CbGeAlD
Lamivudine—ABCG2—female gonad—testicular cancer	0.000526	0.00675	CbGeAlD
Lamivudine—SLC22A3—lymph node—testicular cancer	0.000494	0.00634	CbGeAlD
Lamivudine—ABCC4—lymph node—testicular cancer	0.000479	0.00614	CbGeAlD
Lamivudine—ABCB1—embryo—testicular cancer	0.00047	0.00603	CbGeAlD
Lamivudine—ABCG2—testis—testicular cancer	0.000466	0.00598	CbGeAlD
Lamivudine—ABCC2—lymph node—testicular cancer	0.000464	0.00595	CbGeAlD
Lamivudine—ABCB1—seminal vesicle—testicular cancer	0.000442	0.00566	CbGeAlD
Lamivudine—ABCC1—lymph node—testicular cancer	0.000408	0.00524	CbGeAlD
Lamivudine—ABCG2—lymph node—testicular cancer	0.000338	0.00434	CbGeAlD
Lamivudine—ABCB1—gonad—testicular cancer	0.000319	0.00409	CbGeAlD
Lamivudine—ABCB1—female gonad—testicular cancer	0.000259	0.00333	CbGeAlD
Lamivudine—ABCB1—testis—testicular cancer	0.00023	0.00295	CbGeAlD
Lamivudine—ABCB1—lymph node—testicular cancer	0.000167	0.00214	CbGeAlD
Lamivudine—Stomatitis—Epirubicin—testicular cancer	0.000129	0.000812	CcSEcCtD
Lamivudine—Jaundice—Epirubicin—testicular cancer	0.000129	0.000812	CcSEcCtD
Lamivudine—Constipation—Etoposide—testicular cancer	0.000129	0.000811	CcSEcCtD
Lamivudine—Pain—Etoposide—testicular cancer	0.000129	0.000811	CcSEcCtD
Lamivudine—Dysuria—Doxorubicin—testicular cancer	0.000129	0.000809	CcSEcCtD
Lamivudine—Neutropenia—Doxorubicin—testicular cancer	0.000129	0.000809	CcSEcCtD
Lamivudine—Hepatitis—Methotrexate—testicular cancer	0.000127	0.000799	CcSEcCtD
Lamivudine—Sweating—Epirubicin—testicular cancer	0.000127	0.000799	CcSEcCtD
Lamivudine—Pollakiuria—Doxorubicin—testicular cancer	0.000127	0.000799	CcSEcCtD
Lamivudine—Dizziness—Ifosfamide—testicular cancer	0.000126	0.000794	CcSEcCtD
Lamivudine—Pharyngitis—Methotrexate—testicular cancer	0.000126	0.000793	CcSEcCtD
Lamivudine—Hepatobiliary disease—Epirubicin—testicular cancer	0.000126	0.000788	CcSEcCtD
Lamivudine—Epistaxis—Epirubicin—testicular cancer	0.000125	0.000786	CcSEcCtD
Lamivudine—Sinusitis—Epirubicin—testicular cancer	0.000125	0.000782	CcSEcCtD
Lamivudine—Feeling abnormal—Etoposide—testicular cancer	0.000124	0.000781	CcSEcCtD
Lamivudine—Hyperglycaemia—Doxorubicin—testicular cancer	0.000124	0.00078	CcSEcCtD
Lamivudine—Nausea—Dactinomycin—testicular cancer	0.000124	0.000778	CcSEcCtD
Lamivudine—Agranulocytosis—Epirubicin—testicular cancer	0.000124	0.000778	CcSEcCtD
Lamivudine—Gastrointestinal pain—Etoposide—testicular cancer	0.000124	0.000775	CcSEcCtD
Lamivudine—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000122	0.000765	CcSEcCtD
Lamivudine—Vomiting—Ifosfamide—testicular cancer	0.000122	0.000763	CcSEcCtD
Lamivudine—Hypersensitivity—Cisplatin—testicular cancer	0.000121	0.000763	CcSEcCtD
Lamivudine—Renal failure—Doxorubicin—testicular cancer	0.000121	0.000758	CcSEcCtD
Lamivudine—Rash—Ifosfamide—testicular cancer	0.000121	0.000757	CcSEcCtD
Lamivudine—Dermatitis—Ifosfamide—testicular cancer	0.00012	0.000756	CcSEcCtD
Lamivudine—Erythema multiforme—Methotrexate—testicular cancer	0.00012	0.000756	CcSEcCtD
Lamivudine—Neuropathy peripheral—Doxorubicin—testicular cancer	0.00012	0.000756	CcSEcCtD
Lamivudine—Urticaria—Etoposide—testicular cancer	0.00012	0.000753	CcSEcCtD
Lamivudine—Stomatitis—Doxorubicin—testicular cancer	0.00012	0.000752	CcSEcCtD
Lamivudine—Jaundice—Doxorubicin—testicular cancer	0.00012	0.000752	CcSEcCtD
Lamivudine—Rhinitis—Epirubicin—testicular cancer	0.000119	0.00075	CcSEcCtD
Lamivudine—Abdominal pain—Etoposide—testicular cancer	0.000119	0.00075	CcSEcCtD
Lamivudine—Body temperature increased—Etoposide—testicular cancer	0.000119	0.00075	CcSEcCtD
Lamivudine—Hepatitis—Epirubicin—testicular cancer	0.000119	0.000748	CcSEcCtD
Lamivudine—Hypoaesthesia—Epirubicin—testicular cancer	0.000119	0.000744	CcSEcCtD
Lamivudine—Asthenia—Cisplatin—testicular cancer	0.000118	0.000743	CcSEcCtD
Lamivudine—Pharyngitis—Epirubicin—testicular cancer	0.000118	0.000743	CcSEcCtD
Lamivudine—Sweating—Doxorubicin—testicular cancer	0.000118	0.000739	CcSEcCtD
Lamivudine—Connective tissue disorder—Epirubicin—testicular cancer	0.000117	0.000735	CcSEcCtD
Lamivudine—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000116	0.000729	CcSEcCtD
Lamivudine—Epistaxis—Doxorubicin—testicular cancer	0.000116	0.000727	CcSEcCtD
Lamivudine—Sinusitis—Doxorubicin—testicular cancer	0.000115	0.000723	CcSEcCtD
Lamivudine—Immune system disorder—Methotrexate—testicular cancer	0.000115	0.000722	CcSEcCtD
Lamivudine—Mediastinal disorder—Methotrexate—testicular cancer	0.000115	0.000721	CcSEcCtD
Lamivudine—Agranulocytosis—Doxorubicin—testicular cancer	0.000115	0.00072	CcSEcCtD
Lamivudine—Chills—Methotrexate—testicular cancer	0.000114	0.000717	CcSEcCtD
Lamivudine—Nausea—Ifosfamide—testicular cancer	0.000114	0.000713	CcSEcCtD
Lamivudine—Diarrhoea—Cisplatin—testicular cancer	0.000113	0.000708	CcSEcCtD
Lamivudine—Erythema multiforme—Epirubicin—testicular cancer	0.000113	0.000707	CcSEcCtD
Lamivudine—Alopecia—Methotrexate—testicular cancer	0.000113	0.000706	CcSEcCtD
Lamivudine—Hypersensitivity—Etoposide—testicular cancer	0.000111	0.000699	CcSEcCtD
Lamivudine—Malnutrition—Methotrexate—testicular cancer	0.000111	0.000696	CcSEcCtD
Lamivudine—Erythema—Methotrexate—testicular cancer	0.000111	0.000696	CcSEcCtD
Lamivudine—Rhinitis—Doxorubicin—testicular cancer	0.000111	0.000694	CcSEcCtD
Lamivudine—Hepatitis—Doxorubicin—testicular cancer	0.00011	0.000692	CcSEcCtD
Lamivudine—Hypoaesthesia—Doxorubicin—testicular cancer	0.00011	0.000689	CcSEcCtD
Lamivudine—Pharyngitis—Doxorubicin—testicular cancer	0.000109	0.000687	CcSEcCtD
Lamivudine—Dysgeusia—Methotrexate—testicular cancer	0.000109	0.000682	CcSEcCtD
Lamivudine—Asthenia—Etoposide—testicular cancer	0.000108	0.00068	CcSEcCtD
Lamivudine—Connective tissue disorder—Doxorubicin—testicular cancer	0.000108	0.00068	CcSEcCtD
Lamivudine—Immune system disorder—Epirubicin—testicular cancer	0.000108	0.000676	CcSEcCtD
Lamivudine—Mediastinal disorder—Epirubicin—testicular cancer	0.000107	0.000674	CcSEcCtD
Lamivudine—Back pain—Methotrexate—testicular cancer	0.000107	0.000673	CcSEcCtD
Lamivudine—Chills—Epirubicin—testicular cancer	0.000107	0.000671	CcSEcCtD
Lamivudine—Pruritus—Etoposide—testicular cancer	0.000107	0.000671	CcSEcCtD
Lamivudine—Alopecia—Epirubicin—testicular cancer	0.000105	0.000661	CcSEcCtD
Lamivudine—Vomiting—Cisplatin—testicular cancer	0.000105	0.000658	CcSEcCtD
Lamivudine—Erythema multiforme—Doxorubicin—testicular cancer	0.000104	0.000655	CcSEcCtD
Lamivudine—Rash—Cisplatin—testicular cancer	0.000104	0.000653	CcSEcCtD
Lamivudine—Dermatitis—Cisplatin—testicular cancer	0.000104	0.000652	CcSEcCtD
Lamivudine—Malnutrition—Epirubicin—testicular cancer	0.000104	0.000651	CcSEcCtD
Lamivudine—Erythema—Epirubicin—testicular cancer	0.000104	0.000651	CcSEcCtD
Lamivudine—Diarrhoea—Etoposide—testicular cancer	0.000103	0.000649	CcSEcCtD
Lamivudine—Ill-defined disorder—Methotrexate—testicular cancer	0.000103	0.000646	CcSEcCtD
Lamivudine—Anaemia—Methotrexate—testicular cancer	0.000102	0.000643	CcSEcCtD
Lamivudine—Flatulence—Epirubicin—testicular cancer	0.000102	0.000642	CcSEcCtD
Lamivudine—Tension—Epirubicin—testicular cancer	0.000102	0.000639	CcSEcCtD
Lamivudine—Dysgeusia—Epirubicin—testicular cancer	0.000102	0.000638	CcSEcCtD
Lamivudine—Nervousness—Epirubicin—testicular cancer	0.000101	0.000633	CcSEcCtD
Lamivudine—Back pain—Epirubicin—testicular cancer	0.0001	0.00063	CcSEcCtD
Lamivudine—Malaise—Methotrexate—testicular cancer	0.0001	0.000628	CcSEcCtD
Lamivudine—Dizziness—Etoposide—testicular cancer	9.99e-05	0.000627	CcSEcCtD
Lamivudine—Muscle spasms—Epirubicin—testicular cancer	9.97e-05	0.000626	CcSEcCtD
Lamivudine—Immune system disorder—Doxorubicin—testicular cancer	9.96e-05	0.000625	CcSEcCtD
Lamivudine—Vertigo—Methotrexate—testicular cancer	9.96e-05	0.000625	CcSEcCtD
Lamivudine—Mediastinal disorder—Doxorubicin—testicular cancer	9.94e-05	0.000624	CcSEcCtD
Lamivudine—Leukopenia—Methotrexate—testicular cancer	9.92e-05	0.000623	CcSEcCtD
Lamivudine—Chills—Doxorubicin—testicular cancer	9.89e-05	0.000621	CcSEcCtD
Lamivudine—Nausea—Cisplatin—testicular cancer	9.79e-05	0.000615	CcSEcCtD
Lamivudine—Alopecia—Doxorubicin—testicular cancer	9.74e-05	0.000612	CcSEcCtD
Lamivudine—Cough—Methotrexate—testicular cancer	9.67e-05	0.000607	CcSEcCtD
Lamivudine—Ill-defined disorder—Epirubicin—testicular cancer	9.63e-05	0.000604	CcSEcCtD
Lamivudine—Convulsion—Methotrexate—testicular cancer	9.6e-05	0.000603	CcSEcCtD
Lamivudine—Vomiting—Etoposide—testicular cancer	9.6e-05	0.000603	CcSEcCtD
Lamivudine—Malnutrition—Doxorubicin—testicular cancer	9.6e-05	0.000603	CcSEcCtD
Lamivudine—Erythema—Doxorubicin—testicular cancer	9.6e-05	0.000603	CcSEcCtD
Lamivudine—Anaemia—Epirubicin—testicular cancer	9.59e-05	0.000602	CcSEcCtD
Lamivudine—Rash—Etoposide—testicular cancer	9.52e-05	0.000598	CcSEcCtD
Lamivudine—Dermatitis—Etoposide—testicular cancer	9.51e-05	0.000597	CcSEcCtD
Lamivudine—Headache—Etoposide—testicular cancer	9.46e-05	0.000594	CcSEcCtD
Lamivudine—Flatulence—Doxorubicin—testicular cancer	9.46e-05	0.000594	CcSEcCtD
Lamivudine—Myalgia—Methotrexate—testicular cancer	9.44e-05	0.000592	CcSEcCtD
Lamivudine—Chest pain—Methotrexate—testicular cancer	9.44e-05	0.000592	CcSEcCtD
Lamivudine—Arthralgia—Methotrexate—testicular cancer	9.44e-05	0.000592	CcSEcCtD
Lamivudine—Tension—Doxorubicin—testicular cancer	9.42e-05	0.000591	CcSEcCtD
Lamivudine—Dysgeusia—Doxorubicin—testicular cancer	9.4e-05	0.00059	CcSEcCtD
Lamivudine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	9.37e-05	0.000588	CcSEcCtD
Lamivudine—Malaise—Epirubicin—testicular cancer	9.36e-05	0.000587	CcSEcCtD
Lamivudine—Discomfort—Methotrexate—testicular cancer	9.32e-05	0.000585	CcSEcCtD
Lamivudine—Nervousness—Doxorubicin—testicular cancer	9.32e-05	0.000585	CcSEcCtD
Lamivudine—Vertigo—Epirubicin—testicular cancer	9.32e-05	0.000585	CcSEcCtD
Lamivudine—Syncope—Epirubicin—testicular cancer	9.3e-05	0.000584	CcSEcCtD
Lamivudine—Leukopenia—Epirubicin—testicular cancer	9.29e-05	0.000583	CcSEcCtD
Lamivudine—Back pain—Doxorubicin—testicular cancer	9.28e-05	0.000583	CcSEcCtD
Lamivudine—Muscle spasms—Doxorubicin—testicular cancer	9.23e-05	0.000579	CcSEcCtD
Lamivudine—Confusional state—Methotrexate—testicular cancer	9.12e-05	0.000573	CcSEcCtD
Lamivudine—Loss of consciousness—Epirubicin—testicular cancer	9.12e-05	0.000572	CcSEcCtD
Lamivudine—Cough—Epirubicin—testicular cancer	9.05e-05	0.000568	CcSEcCtD
Lamivudine—Anaphylactic shock—Methotrexate—testicular cancer	9.05e-05	0.000568	CcSEcCtD
Lamivudine—Convulsion—Epirubicin—testicular cancer	8.99e-05	0.000564	CcSEcCtD
Lamivudine—Infection—Methotrexate—testicular cancer	8.99e-05	0.000564	CcSEcCtD
Lamivudine—Nausea—Etoposide—testicular cancer	8.97e-05	0.000563	CcSEcCtD
Lamivudine—Ill-defined disorder—Doxorubicin—testicular cancer	8.91e-05	0.000559	CcSEcCtD
Lamivudine—Nervous system disorder—Methotrexate—testicular cancer	8.87e-05	0.000557	CcSEcCtD
Lamivudine—Anaemia—Doxorubicin—testicular cancer	8.87e-05	0.000557	CcSEcCtD
Lamivudine—Thrombocytopenia—Methotrexate—testicular cancer	8.86e-05	0.000556	CcSEcCtD
Lamivudine—Arthralgia—Epirubicin—testicular cancer	8.83e-05	0.000554	CcSEcCtD
Lamivudine—Chest pain—Epirubicin—testicular cancer	8.83e-05	0.000554	CcSEcCtD
Lamivudine—Myalgia—Epirubicin—testicular cancer	8.83e-05	0.000554	CcSEcCtD
Lamivudine—Anxiety—Epirubicin—testicular cancer	8.8e-05	0.000553	CcSEcCtD
Lamivudine—Skin disorder—Methotrexate—testicular cancer	8.79e-05	0.000552	CcSEcCtD
Lamivudine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	8.77e-05	0.000551	CcSEcCtD
Lamivudine—Hyperhidrosis—Methotrexate—testicular cancer	8.75e-05	0.000549	CcSEcCtD
Lamivudine—Discomfort—Epirubicin—testicular cancer	8.73e-05	0.000548	CcSEcCtD
Lamivudine—Malaise—Doxorubicin—testicular cancer	8.66e-05	0.000543	CcSEcCtD
Lamivudine—Dry mouth—Epirubicin—testicular cancer	8.64e-05	0.000542	CcSEcCtD
Lamivudine—Vertigo—Doxorubicin—testicular cancer	8.62e-05	0.000541	CcSEcCtD
Lamivudine—Anorexia—Methotrexate—testicular cancer	8.62e-05	0.000541	CcSEcCtD
Lamivudine—Syncope—Doxorubicin—testicular cancer	8.61e-05	0.00054	CcSEcCtD
Lamivudine—Leukopenia—Doxorubicin—testicular cancer	8.59e-05	0.000539	CcSEcCtD
Lamivudine—Confusional state—Epirubicin—testicular cancer	8.54e-05	0.000536	CcSEcCtD
Lamivudine—Oedema—Epirubicin—testicular cancer	8.47e-05	0.000532	CcSEcCtD
Lamivudine—Anaphylactic shock—Epirubicin—testicular cancer	8.47e-05	0.000532	CcSEcCtD
Lamivudine—Hypotension—Methotrexate—testicular cancer	8.45e-05	0.000531	CcSEcCtD
Lamivudine—Loss of consciousness—Doxorubicin—testicular cancer	8.44e-05	0.00053	CcSEcCtD
Lamivudine—Infection—Epirubicin—testicular cancer	8.41e-05	0.000528	CcSEcCtD
Lamivudine—Cough—Doxorubicin—testicular cancer	8.38e-05	0.000526	CcSEcCtD
Lamivudine—Shock—Epirubicin—testicular cancer	8.33e-05	0.000523	CcSEcCtD
Lamivudine—Convulsion—Doxorubicin—testicular cancer	8.32e-05	0.000522	CcSEcCtD
Lamivudine—Nervous system disorder—Epirubicin—testicular cancer	8.3e-05	0.000521	CcSEcCtD
Lamivudine—Thrombocytopenia—Epirubicin—testicular cancer	8.29e-05	0.00052	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Methotrexate—testicular cancer	8.24e-05	0.000517	CcSEcCtD
Lamivudine—Skin disorder—Epirubicin—testicular cancer	8.22e-05	0.000516	CcSEcCtD
Lamivudine—Hyperhidrosis—Epirubicin—testicular cancer	8.18e-05	0.000514	CcSEcCtD
Lamivudine—Insomnia—Methotrexate—testicular cancer	8.18e-05	0.000514	CcSEcCtD
Lamivudine—Arthralgia—Doxorubicin—testicular cancer	8.17e-05	0.000513	CcSEcCtD
Lamivudine—Chest pain—Doxorubicin—testicular cancer	8.17e-05	0.000513	CcSEcCtD
Lamivudine—Myalgia—Doxorubicin—testicular cancer	8.17e-05	0.000513	CcSEcCtD
Lamivudine—Anxiety—Doxorubicin—testicular cancer	8.14e-05	0.000511	CcSEcCtD
Lamivudine—Paraesthesia—Methotrexate—testicular cancer	8.12e-05	0.00051	CcSEcCtD
Lamivudine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	8.12e-05	0.00051	CcSEcCtD
Lamivudine—Discomfort—Doxorubicin—testicular cancer	8.07e-05	0.000507	CcSEcCtD
Lamivudine—Anorexia—Epirubicin—testicular cancer	8.07e-05	0.000507	CcSEcCtD
Lamivudine—Dyspnoea—Methotrexate—testicular cancer	8.07e-05	0.000506	CcSEcCtD
Lamivudine—Somnolence—Methotrexate—testicular cancer	8.04e-05	0.000505	CcSEcCtD
Lamivudine—Dry mouth—Doxorubicin—testicular cancer	7.99e-05	0.000502	CcSEcCtD
Lamivudine—Dyspepsia—Methotrexate—testicular cancer	7.96e-05	0.0005	CcSEcCtD
Lamivudine—Hypotension—Epirubicin—testicular cancer	7.91e-05	0.000497	CcSEcCtD
Lamivudine—Confusional state—Doxorubicin—testicular cancer	7.9e-05	0.000496	CcSEcCtD
Lamivudine—Decreased appetite—Methotrexate—testicular cancer	7.86e-05	0.000494	CcSEcCtD
Lamivudine—Anaphylactic shock—Doxorubicin—testicular cancer	7.83e-05	0.000492	CcSEcCtD
Lamivudine—Oedema—Doxorubicin—testicular cancer	7.83e-05	0.000492	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Methotrexate—testicular cancer	7.81e-05	0.00049	CcSEcCtD
Lamivudine—Fatigue—Methotrexate—testicular cancer	7.8e-05	0.00049	CcSEcCtD
Lamivudine—Infection—Doxorubicin—testicular cancer	7.78e-05	0.000489	CcSEcCtD
Lamivudine—Pain—Methotrexate—testicular cancer	7.74e-05	0.000486	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Epirubicin—testicular cancer	7.71e-05	0.000484	CcSEcCtD
Lamivudine—Shock—Doxorubicin—testicular cancer	7.71e-05	0.000484	CcSEcCtD
Lamivudine—Nervous system disorder—Doxorubicin—testicular cancer	7.68e-05	0.000482	CcSEcCtD
Lamivudine—Thrombocytopenia—Doxorubicin—testicular cancer	7.67e-05	0.000482	CcSEcCtD
Lamivudine—Insomnia—Epirubicin—testicular cancer	7.66e-05	0.000481	CcSEcCtD
Lamivudine—Skin disorder—Doxorubicin—testicular cancer	7.61e-05	0.000478	CcSEcCtD
Lamivudine—Paraesthesia—Epirubicin—testicular cancer	7.6e-05	0.000477	CcSEcCtD
Lamivudine—Hyperhidrosis—Doxorubicin—testicular cancer	7.57e-05	0.000475	CcSEcCtD
Lamivudine—Dyspnoea—Epirubicin—testicular cancer	7.55e-05	0.000474	CcSEcCtD
Lamivudine—Somnolence—Epirubicin—testicular cancer	7.53e-05	0.000473	CcSEcCtD
Lamivudine—Anorexia—Doxorubicin—testicular cancer	7.47e-05	0.000469	CcSEcCtD
Lamivudine—Feeling abnormal—Methotrexate—testicular cancer	7.46e-05	0.000468	CcSEcCtD
Lamivudine—Dyspepsia—Epirubicin—testicular cancer	7.45e-05	0.000468	CcSEcCtD
Lamivudine—Gastrointestinal pain—Methotrexate—testicular cancer	7.4e-05	0.000464	CcSEcCtD
Lamivudine—Decreased appetite—Epirubicin—testicular cancer	7.36e-05	0.000462	CcSEcCtD
Lamivudine—Hypotension—Doxorubicin—testicular cancer	7.32e-05	0.00046	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Epirubicin—testicular cancer	7.31e-05	0.000459	CcSEcCtD
Lamivudine—Fatigue—Epirubicin—testicular cancer	7.3e-05	0.000458	CcSEcCtD
Lamivudine—Pain—Epirubicin—testicular cancer	7.24e-05	0.000455	CcSEcCtD
Lamivudine—Constipation—Epirubicin—testicular cancer	7.24e-05	0.000455	CcSEcCtD
Lamivudine—Urticaria—Methotrexate—testicular cancer	7.19e-05	0.000451	CcSEcCtD
Lamivudine—Abdominal pain—Methotrexate—testicular cancer	7.15e-05	0.000449	CcSEcCtD
Lamivudine—Body temperature increased—Methotrexate—testicular cancer	7.15e-05	0.000449	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Doxorubicin—testicular cancer	7.14e-05	0.000448	CcSEcCtD
Lamivudine—Insomnia—Doxorubicin—testicular cancer	7.09e-05	0.000445	CcSEcCtD
Lamivudine—Paraesthesia—Doxorubicin—testicular cancer	7.03e-05	0.000442	CcSEcCtD
Lamivudine—Dyspnoea—Doxorubicin—testicular cancer	6.98e-05	0.000438	CcSEcCtD
Lamivudine—Feeling abnormal—Epirubicin—testicular cancer	6.98e-05	0.000438	CcSEcCtD
Lamivudine—Somnolence—Doxorubicin—testicular cancer	6.96e-05	0.000437	CcSEcCtD
Lamivudine—Gastrointestinal pain—Epirubicin—testicular cancer	6.92e-05	0.000435	CcSEcCtD
Lamivudine—Dyspepsia—Doxorubicin—testicular cancer	6.9e-05	0.000433	CcSEcCtD
Lamivudine—Decreased appetite—Doxorubicin—testicular cancer	6.81e-05	0.000428	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Doxorubicin—testicular cancer	6.76e-05	0.000425	CcSEcCtD
Lamivudine—Fatigue—Doxorubicin—testicular cancer	6.75e-05	0.000424	CcSEcCtD
Lamivudine—Urticaria—Epirubicin—testicular cancer	6.73e-05	0.000422	CcSEcCtD
Lamivudine—Pain—Doxorubicin—testicular cancer	6.7e-05	0.000421	CcSEcCtD
Lamivudine—Constipation—Doxorubicin—testicular cancer	6.7e-05	0.000421	CcSEcCtD
Lamivudine—Abdominal pain—Epirubicin—testicular cancer	6.69e-05	0.00042	CcSEcCtD
Lamivudine—Body temperature increased—Epirubicin—testicular cancer	6.69e-05	0.00042	CcSEcCtD
Lamivudine—Hypersensitivity—Methotrexate—testicular cancer	6.67e-05	0.000418	CcSEcCtD
Lamivudine—Asthenia—Methotrexate—testicular cancer	6.49e-05	0.000408	CcSEcCtD
Lamivudine—Feeling abnormal—Doxorubicin—testicular cancer	6.46e-05	0.000405	CcSEcCtD
Lamivudine—Gastrointestinal pain—Doxorubicin—testicular cancer	6.41e-05	0.000402	CcSEcCtD
Lamivudine—Pruritus—Methotrexate—testicular cancer	6.4e-05	0.000402	CcSEcCtD
Lamivudine—Hypersensitivity—Epirubicin—testicular cancer	6.24e-05	0.000392	CcSEcCtD
Lamivudine—Urticaria—Doxorubicin—testicular cancer	6.22e-05	0.000391	CcSEcCtD
Lamivudine—Abdominal pain—Doxorubicin—testicular cancer	6.19e-05	0.000389	CcSEcCtD
Lamivudine—Body temperature increased—Doxorubicin—testicular cancer	6.19e-05	0.000389	CcSEcCtD
Lamivudine—Diarrhoea—Methotrexate—testicular cancer	6.19e-05	0.000389	CcSEcCtD
Lamivudine—Asthenia—Epirubicin—testicular cancer	6.07e-05	0.000381	CcSEcCtD
Lamivudine—Pruritus—Epirubicin—testicular cancer	5.99e-05	0.000376	CcSEcCtD
Lamivudine—Dizziness—Methotrexate—testicular cancer	5.98e-05	0.000376	CcSEcCtD
Lamivudine—Diarrhoea—Epirubicin—testicular cancer	5.79e-05	0.000364	CcSEcCtD
Lamivudine—Hypersensitivity—Doxorubicin—testicular cancer	5.77e-05	0.000362	CcSEcCtD
Lamivudine—Vomiting—Methotrexate—testicular cancer	5.75e-05	0.000361	CcSEcCtD
Lamivudine—Rash—Methotrexate—testicular cancer	5.7e-05	0.000358	CcSEcCtD
Lamivudine—Dermatitis—Methotrexate—testicular cancer	5.7e-05	0.000358	CcSEcCtD
Lamivudine—Headache—Methotrexate—testicular cancer	5.67e-05	0.000356	CcSEcCtD
Lamivudine—Asthenia—Doxorubicin—testicular cancer	5.62e-05	0.000353	CcSEcCtD
Lamivudine—Dizziness—Epirubicin—testicular cancer	5.6e-05	0.000351	CcSEcCtD
Lamivudine—Pruritus—Doxorubicin—testicular cancer	5.54e-05	0.000348	CcSEcCtD
Lamivudine—Vomiting—Epirubicin—testicular cancer	5.38e-05	0.000338	CcSEcCtD
Lamivudine—Nausea—Methotrexate—testicular cancer	5.37e-05	0.000337	CcSEcCtD
Lamivudine—Diarrhoea—Doxorubicin—testicular cancer	5.36e-05	0.000337	CcSEcCtD
Lamivudine—Rash—Epirubicin—testicular cancer	5.34e-05	0.000335	CcSEcCtD
Lamivudine—Dermatitis—Epirubicin—testicular cancer	5.33e-05	0.000335	CcSEcCtD
Lamivudine—Headache—Epirubicin—testicular cancer	5.3e-05	0.000333	CcSEcCtD
Lamivudine—Dizziness—Doxorubicin—testicular cancer	5.18e-05	0.000325	CcSEcCtD
Lamivudine—Nausea—Epirubicin—testicular cancer	5.03e-05	0.000316	CcSEcCtD
Lamivudine—Vomiting—Doxorubicin—testicular cancer	4.98e-05	0.000313	CcSEcCtD
Lamivudine—Rash—Doxorubicin—testicular cancer	4.94e-05	0.00031	CcSEcCtD
Lamivudine—Dermatitis—Doxorubicin—testicular cancer	4.93e-05	0.00031	CcSEcCtD
Lamivudine—Headache—Doxorubicin—testicular cancer	4.91e-05	0.000308	CcSEcCtD
Lamivudine—Nausea—Doxorubicin—testicular cancer	4.65e-05	0.000292	CcSEcCtD
